Quintrio
Home

Stock overview

NewcelX Ltd. Ordinary Shares

NCEL

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.00 – $2.66
Volume 6,646
Market cap $16M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for NCEL.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for NCEL.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

NewcelX Ltd. (Nasdaq: NCEL) announced a binding term sheet to divest its Mazindol asset portfolio to REA Holdings Inc. for $500,000 upfront ($30,000 cash and $470,000 in equity representing 9.4% stake), plus up to $55 million in potential milestone payments and tiered royalties of 2-8% on global net sales. The divestiture allows NewcelX to focus on its core cell-therapy pipeline for Type 1 Diabetes while preserving potential value for CVR holders.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.